GERD is Chronic backflow of stomach acid into the esophagus.

Dyspepsia is Persistent or recurring upper abdominal pain.

Peptic Disorder is broad term encompassing conditions like peptic ulcers and gastritis, often caused by Helicobacter pylori infection or NSAID.

MOA : Rabeprazole acts as a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme in gastric parietal cells, reducing gastric acid secretion. Domperidone is a dopamine antagonist that enhances gastrointestinal motility, reduces nausea and vomiting, and prevents reflux by increasing lower esophageal sphincter tone.

GERD is Chronic backflow of stomach acid into the esophagus.

Dyspepsia is persistent or recurring upper abdominal pain.

Peptic Disorder is broad term encompassing conditions like peptic ulcers and gastritis, often caused by Helicobacter pylori infection or NSAID.

MOA : Pantoprazole act ac a proton pump inhibitor (PPI) that reduces gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in gastric parietal cells. Domperidone is a dopamine antagonist that enhances gastrointestinal motility, reduces nausea and vomiting, and prevents reflux by increasing lower esophageal sphincter tone.

GERD is Chronic backflow of stomach acid into the esophagus.

Dyspepsia is Persistent or recurring upper abdominal pain.

Peptic Disorder is broad term encompassing conditions like peptic ulcers and gastritis, often caused by Helicobacter pylori infection or NSAID.

MOA : Pantoprazole act ac a proton pump inhibitor (PPI) that reduces gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in gastric parietal cells. Domperidone is a dopamine antagonist that enhances gastrointestinal motility, reduces nausea and vomiting, and prevents reflux by increasing lower esophageal sphincter tone.

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : Vildagliptin Inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1 and GIP), which stimulate insulin release and decrease glucagon levels. Metformin activates AMPK and reduce hepatic glucose levels.

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : It Inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1 and GIP-2), which stimulate insulin release and decrease glucagon levels.

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : Glimepiride stimulates insulin release from pancreatic beta cells by closing ATPsensitive potassium channels. Voglibose acts as an alpha-glucosidase inhibitor, used to treat type 2 diabetes by delaying carbohydrate digestion and absorption, thereby reducing postprandial blood glucose peaks. Metformin activates AMPK and reduce hepatic glucose levels.

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : Glimepiride stimulates insulin release from pancreatic beta cells by closing ATPsensitive potassium channels. Metformin activates AMPK and reduce hepatic glucose levels

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : Voglibose acts as an alpha-glucosidase inhibitor, used to treat type 2 diabetes by delaying carbohydrate digestion and absorption, thereby reducing postprandial blood glucose peaks. Metformin activates AMPK and reduce hepatic glucose levels.

Type 2 Diabetes mellitus a chronic condition that affects the way the body processes blood sugar.

MOA : Voglibose acts as an alpha – glucosidase inhibitor, used to treat type 2 diabetes by delaying carbohydrate digestion and absorption, thereby reducing postprandial blood glucose peaks.